NCT00621322View on ClinicalTrials.gov

Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults

PHASE2CompletedINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

April 3, 2008

Primary Completion Date

April 3, 2009

Study Completion Date

April 3, 2009

Conditions

Tuberculosis

Interventions

BIOLOGICAL

GSK Biologicals' AS01B adjuvant

Intramuscular injection, 2 doses

BIOLOGICAL

GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1

Intramuscular injection, 2 doses

BIOLOGICAL

GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2

Intramuscular injection, 2 doses

BIOLOGICAL

GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3

Intramuscular injection, 2 doses

BIOLOGICAL

GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1

Intramuscular injection, 2 doses

BIOLOGICAL

GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2

Intramuscular injection, 2 doses

Trial Locations (1)

1000

GSK Investigational Site, Manila

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY